BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15591091)

  • 1. Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.
    Lubet RA; Christov K; Nunez NP; Hursting SD; Steele VE; Juliana MM; Eto I; Grubbs CJ
    Carcinogenesis; 2005 Feb; 26(2):441-8. PubMed ID: 15591091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.
    Christov K; Grubbs CJ; Shilkaitis A; Juliana MM; Lubet RA
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5488-96. PubMed ID: 17875779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.
    Grubbs CJ; Lubet RA; Atigadda VR; Christov K; Deshpande AM; Tirmal V; Xia G; Bland KI; Eto I; Brouillette WJ; Muccio DD
    Carcinogenesis; 2006 Jun; 27(6):1232-9. PubMed ID: 16344269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
    Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
    Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
    Lubet RA; Boring D; Steele VE; Ruppert JM; Juliana MM; Grubbs CJ
    Cancer Prev Res (Phila); 2009 Feb; 2(2):161-7. PubMed ID: 19196723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations.
    Lubet RA; Gordon GB; Prough RA; Lei XD; You M; Wang Y; Grubbs CJ; Steele VE; Kelloff GJ; Thomas CF; Moon RD
    Cancer Res; 1998 Mar; 58(5):921-6. PubMed ID: 9500451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
    Cohen LA; Marks PA; Rifkind RA; Amin S; Desai D; Pittman B; Richon VM
    Anticancer Res; 2002; 22(3):1497-504. PubMed ID: 12168829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
    Agarwal VR; Bischoff ED; Hermann T; Lamph WW
    Cancer Res; 2000 Nov; 60(21):6033-8. PubMed ID: 11085524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.
    Lubet RA; Steele VE; DeCoster R; Bowden C; You M; Juliana MM; Eto I; Kelloff GJ; Grubbs CJ
    Carcinogenesis; 1998 Aug; 19(8):1345-51. PubMed ID: 9744527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low zinc intake suppressed N-methyl-N-nitrosourea-induced mammary tumorigenesis in Sprague-Dawley rats.
    Lee S; Simpson M; Nimmo M; Xu Z
    Carcinogenesis; 2004 Oct; 25(10):1879-85. PubMed ID: 15205360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
    Gottardis MM; Bischoff ED; Shirley MA; Wagoner MA; Lamph WW; Heyman RA
    Cancer Res; 1996 Dec; 56(24):5566-70. PubMed ID: 8971154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology.
    Rodríguez-Burford C; Steele VE; Anderson AS; Stockard CR; Weiss HL; Eto I; Johanning GL; Grizzle WE; Grubbs CJ
    Nutr Cancer; 2002; 43(1):67-75. PubMed ID: 12467137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
    Lubet RA; Clapper ML; McCormick DL; Pereira MA; Chang WC; Steele VE; Fischer SM; Juliana MM; Grubbs CJ
    Oncol Rep; 2012 May; 27(5):1400-6. PubMed ID: 22307264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
    Lubet RA; Szabo E; Christov K; Bode AM; Ericson ME; Steele VE; Juliana MM; Grubbs CJ
    Mol Cancer Ther; 2008 Apr; 7(4):972-9. PubMed ID: 18375820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
    Gamage SD; Bischoff ED; Burroughs KD; Lamph WW; Gottardis MM; Walker CL; Fuchs-Young R
    J Pharmacol Exp Ther; 2000 Nov; 295(2):677-81. PubMed ID: 11046105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
    Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequency.
    Swanson SM; Christov K
    Anticancer Res; 2003; 23(4):3207-13. PubMed ID: 12931682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas.
    Zhu Z; Jiang W; Thompson HJ
    Carcinogenesis; 2003 Jul; 24(7):1225-31. PubMed ID: 12807724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland.
    McCormick DL; Rao KV; Johnson WD; Bowman-Gram TA; Steele VE; Lubet RA; Kellof GJ
    Cancer Res; 1996 Apr; 56(8):1724-6. PubMed ID: 8620482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen.
    Moon RC; Kelloff GJ; Detrisac CJ; Steele VE; Thomas CF; Sigman CC
    Anticancer Res; 1992; 12(4):1147-53. PubMed ID: 1386970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.